Swiss Nordic Bio 2026: Hemispherian's oncology approach is to target the TET2 enzyme - with the aim to restore the cancer cell’s normal epigenetic complement
CEO Zeno Albisser describes this target and the company's work to focus on it - their lead asset is in the clinic and is partnered with BioLineRx.
Coverage brought to you by










.png)